| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0950 x N/A |
| Ask | 0.1050 x N/A |
| Day's Range | 0.1000 - 0.1000 |
| 52 Week Range | 0.0650 - 0.4500 |
| Volume | 10,000 |
| Avg. Volume | 94,752 |
| Market Cap | 6.319M |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0320 |
| Earnings Date | Apr. 23, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 21, 2021 / Pascal Biosciences, Inc. ("Pascal" or the "Company") (TSXV:PAS)(OTC PINK:BIMUF), will present at the first Cannabinoid Derived Pharmaceuticals Industry Review Summit today.
- ACCESSWIRE
Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / December 8, 2020 / December 2, 2020 / Pascal Biosciences Inc.
- ACCESSWIRE
Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / November 10, 2020 / Pascal Biosciences Inc.
© 2021 Verizon Media. All rights reserved.
